153 related items for PubMed ID: 26222760
21. Ulinastatin therapy in kawasaki disease.
Iwashima S, Seguchi M, Matubayashi T, Ohzeki T.
Clin Drug Investig; 2007; 27(10):691-6. PubMed ID: 17803344
[Abstract] [Full Text] [Related]
22. Do cytokines correlate with refractory Kawasaki disease in children?
Wang Y, Qian SY, Yuan Y, Wang Q, Gao L, Chen X, Yu X, Zhen Z.
Clin Chim Acta; 2020 Jul; 506():222-227. PubMed ID: 32156603
[Abstract] [Full Text] [Related]
23. Prediction of repeated intravenous immunoglobulin resistance in children with Kawasaki disease.
Lu Y, Chen T, Wen Y, Si F, Wu X, Yang Y.
BMC Pediatr; 2021 Sep 16; 21(1):406. PubMed ID: 34530763
[Abstract] [Full Text] [Related]
24. New predictors to identify severe cases during intravenous immunoglobulin therapy in Kawasaki disease.
Iwasa M, Inukai S.
Pediatr Int; 2022 Jan 16; 64(1):e15142. PubMed ID: 35522824
[Abstract] [Full Text] [Related]
25. [Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study].
Qin LJ, Wang HW, Hu XF, Liu QJ, Shi H, Wei YX, Chen QJ, Cheng PX.
Zhonghua Er Ke Za Zhi; 2006 Dec 16; 44(12):891-5. PubMed ID: 17254453
[Abstract] [Full Text] [Related]
26. Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial.
Ogata S, Ogihara Y, Honda T, Kon S, Akiyama K, Ishii M.
Pediatrics; 2012 Jan 16; 129(1):e17-23. PubMed ID: 22144699
[Abstract] [Full Text] [Related]
27. Seasonality of i.v. immunoglobulin responsiveness in Kawasaki disease.
Kido S, Ae R, Kosami K, Matsubara Y, Makino N, Sasahara T, Kuwabara M, Aoyama Y, Yashiro M, Yanagawa H, Nakamura Y.
Pediatr Int; 2019 Jun 16; 61(6):539-543. PubMed ID: 30980447
[Abstract] [Full Text] [Related]
28. Evaluation of laboratory predictors for intravenous immunoglobulin resistance and coronary artery aneurysm in Kawasaki Disease before and after therapy.
Liu J, Ye B, Su D, Qin S, Zhao W, Pang Y.
Clin Rheumatol; 2023 Jan 16; 42(1):167-177. PubMed ID: 36129563
[Abstract] [Full Text] [Related]
29. Role of glucocorticoids in Kawasaki disease.
Miura M.
Int J Rheum Dis; 2018 Jan 16; 21(1):70-75. PubMed ID: 29105310
[Abstract] [Full Text] [Related]
30. Variability in Response to Intravenous Immunoglobulin in the Treatment of Kawasaki Disease.
Downie ML, Manlhiot C, Latino GA, Collins TH, Chahal N, Yeung RS, McCrindle BW.
J Pediatr; 2016 Dec 16; 179():124-130.e1. PubMed ID: 27659027
[Abstract] [Full Text] [Related]
31. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
Furukawa T, Kishiro M, Akimoto K, Nagata S, Shimizu T, Yamashiro Y.
Arch Dis Child; 2008 Feb 16; 93(2):142-6. PubMed ID: 17962370
[Abstract] [Full Text] [Related]
32. Inflammatory cytokines as predictors of resistance to intravenous immunoglobulin therapy in Kawasaki disease patients.
Sato S, Kawashima H, Kashiwagi Y, Hoshika A.
Int J Rheum Dis; 2013 Apr 16; 16(2):168-72. PubMed ID: 23773640
[Abstract] [Full Text] [Related]
33. Prediction Models for Intravenous Immunoglobulin Non-Responders of Kawasaki Disease Using Machine Learning.
Miyagi Y, Iwashima S.
Clin Drug Investig; 2024 Jun 16; 44(6):425-437. PubMed ID: 38869717
[Abstract] [Full Text] [Related]
34. A Multicenter Study of Intravenous Immunoglobulin Non-response in Kawasaki Disease.
Wei M, Huang M, Chen S, Huang G, Huang M, Qiu D, Guo Z, Jiang J, Zhou X, Yu Q, Guo Y, Fu L, Gao W, Li F.
Pediatr Cardiol; 2015 Aug 16; 36(6):1166-72. PubMed ID: 25812827
[Abstract] [Full Text] [Related]
35. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
Tse SM, Silverman ED, McCrindle BW, Yeung RS.
J Pediatr; 2002 Apr 16; 140(4):450-5. PubMed ID: 12006960
[Abstract] [Full Text] [Related]
36. Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease.
Han CL, Zhao SL.
Med Sci Monit; 2018 Oct 11; 24():7264-7270. PubMed ID: 30307902
[Abstract] [Full Text] [Related]
37. Value of C-reactive protein/albumin ratio in predicting intravenous immunoglobulin-resistant Kawasaki disease- a data from multi-institutional study in China.
Li G, Wang T, Gou Y, Zeng R, Liu D, Duan Y, Liu B.
Int Immunopharmacol; 2020 Dec 11; 89(Pt A):107037. PubMed ID: 33242833
[Abstract] [Full Text] [Related]
38. Risk Factors of Coronary Artery Aneurysms in Kawasaki Disease with a Low Risk of Intravenous Immunoglobulin Resistance: An Analysis of Post RAISE.
Iio K, Morikawa Y, Miyata K, Kaneko T, Misawa M, Yamagishi H, Miura M.
J Pediatr; 2022 Jan 11; 240():158-163.e4. PubMed ID: 34461064
[Abstract] [Full Text] [Related]
39. High neutrophil : lymphocyte ratio is associated with refractory Kawasaki disease.
Cho HJ, Bak SY, Kim SY, Yoo R, Baek HS, Yang S, Hwang IT, Ban JE.
Pediatr Int; 2017 Jun 11; 59(6):669-674. PubMed ID: 28097746
[Abstract] [Full Text] [Related]
40. Sivelestat sodium hydrate treatment for refractory Kawasaki disease.
Ebata R, Yasukawa K, Nagai K, Saito Y, Higashi K, Homma J, Takada N, Takechi F, Saito N, Kobayashi H, Okunushi K, Hamada H, Kohno Y, Hanaoka H, Shimojo N.
Pediatr Int; 2019 May 11; 61(5):438-443. PubMed ID: 30916859
[Abstract] [Full Text] [Related]
Page: [Previous] [Next] [New Search]
